Matches in Wikidata for { <http://www.wikidata.org/entity/Q91396547> ?p ?o ?g. }
Showing items 1 to 65 of
65
with 100 items per page.
- Q91396547 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q91396547 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91396547 description "scientific article published on 01 March 2019" @default.
- Q91396547 description "wetenschappelijk artikel" @default.
- Q91396547 description "наукова стаття, опублікована 1 березня 2019" @default.
- Q91396547 description "գիտական հոդված հրատարակված 2019 թվականի մարտի 1-ին" @default.
- Q91396547 name "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 name "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 type Item @default.
- Q91396547 label "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 label "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 prefLabel "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 prefLabel "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 P1433 Q91396547-C8FE3975-167C-47E6-B206-952CE9FFE4A3 @default.
- Q91396547 P1476 Q91396547-3F12A7F8-F973-4C94-8F9C-DD40968BA759 @default.
- Q91396547 P2093 Q91396547-4B0FA6D6-BD5B-409C-82C7-06652F9338A7 @default.
- Q91396547 P2093 Q91396547-52B59752-6549-448B-ADBA-016FE059C0D8 @default.
- Q91396547 P2093 Q91396547-592C7911-7BC1-433F-9834-5AB529998287 @default.
- Q91396547 P2093 Q91396547-5A4D7268-1D33-472A-8FA5-DD1FF88142E5 @default.
- Q91396547 P2093 Q91396547-5FB308C8-B553-4C76-9C7A-A32B54DE1489 @default.
- Q91396547 P2093 Q91396547-68FB6A5C-F126-4D32-81BE-0415D2A447D8 @default.
- Q91396547 P2093 Q91396547-6ECD7F88-82AF-4E9C-BC30-B8F620515374 @default.
- Q91396547 P2093 Q91396547-70C7E332-2832-42CE-AF3B-DE2FBEC972D2 @default.
- Q91396547 P2093 Q91396547-73C527EA-2C69-463D-BCDC-D25569201542 @default.
- Q91396547 P2093 Q91396547-7CBAD83E-892C-476D-8F99-C3CAC6B81DBA @default.
- Q91396547 P2093 Q91396547-B85D34DE-B26B-4A21-BF03-E56CB273ACFF @default.
- Q91396547 P2093 Q91396547-C2D50A31-5A05-4289-A2F2-8F2B10EE2168 @default.
- Q91396547 P275 Q91396547-a651a89a-1b04-48b1-b767-5e75527d9554 @default.
- Q91396547 P304 Q91396547-AD3F74FB-F3DF-4693-9301-BC212A847331 @default.
- Q91396547 P31 Q91396547-E0ED96EB-1B5B-4479-B249-48E5F6EBF401 @default.
- Q91396547 P31 Q91396547-F140A29D-5997-4670-8A30-4EF4594C5487 @default.
- Q91396547 P356 Q91396547-B4213E2F-6B20-4E32-85B4-82FEFAF0E093 @default.
- Q91396547 P433 Q91396547-6F3C6200-B044-4F44-A9F2-E6CD13DF4C3B @default.
- Q91396547 P478 Q91396547-11E18ADA-8C7B-4629-B724-9F5F56D0387B @default.
- Q91396547 P577 Q91396547-33B3FB8A-9D8B-4EB4-9EF7-1FCB8A6B7973 @default.
- Q91396547 P6216 Q91396547-fd3a26e8-c3f4-4f2d-b229-a6589c7ad36d @default.
- Q91396547 P698 Q91396547-DAF3E4B9-D2B0-491D-81F5-D69186AB6FDB @default.
- Q91396547 P932 Q91396547-2EC49F9B-3459-478B-895A-C12819F635DB @default.
- Q91396547 P356 S41669-018-0096-X @default.
- Q91396547 P698 30206825 @default.
- Q91396547 P1433 Q27056937 @default.
- Q91396547 P1476 "Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England" @default.
- Q91396547 P2093 "A Amadi" @default.
- Q91396547 P2093 "A Walker" @default.
- Q91396547 P2093 "D Lee" @default.
- Q91396547 P2093 "H Johnson" @default.
- Q91396547 P2093 "J Ellis" @default.
- Q91396547 P2093 "J Sabater" @default.
- Q91396547 P2093 "K Patterson" @default.
- Q91396547 P2093 "M Cooper" @default.
- Q91396547 P2093 "N Roskell" @default.
- Q91396547 P2093 "S Kotapati" @default.
- Q91396547 P2093 "S McNamara" @default.
- Q91396547 P2093 "Y Meng" @default.
- Q91396547 P275 Q34179348 @default.
- Q91396547 P304 "127" @default.
- Q91396547 P31 Q13442814 @default.
- Q91396547 P31 Q1348305 @default.
- Q91396547 P356 "10.1007/S41669-018-0096-X" @default.
- Q91396547 P433 "1" @default.
- Q91396547 P478 "3" @default.
- Q91396547 P577 "2019-03-01T00:00:00Z" @default.
- Q91396547 P6216 Q50423863 @default.
- Q91396547 P698 "30206825" @default.
- Q91396547 P932 "6393273" @default.